Literature DB >> 17602726

A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.

Giovanni D Aletti1, Antonio Santillan, Eric L Eisenhauer, Jae Hu, Giacomo Aletti, Karl C Podratz, Robert E Bristow, Dennis S Chi, William A Cliby.   

Abstract

OBJECTIVE: To test the feasibility and utility of a risk-adjusted, multicenter outcomes model for ovarian cancer surgery as a tool for quality improvement.
METHODS: Patient characteristics, intra-operative findings, procedures, and outcomes were assessed in primary advanced stage ovarian cancer cases from 3 independent centers. A surgical complexity score (SCS) was developed to adjust for extent of surgery. Outcomes measures were: 30-day morbidity (sepsis, thrombo-embolic, cardiac, readmission or re-operation), 3-month mortality, length of stay (LOS), and ability to receive chemotherapy. A multivariable risk-adjusted model was developed for all the outcomes. Observed-to-expected (O/E) outcome ratios were calculated from all data.
RESULTS: 564 consecutive patients from 3 centers were analyzed. The strongest predictors of 30-day morbidity were endogenous [albumin (p<0.001) and ASA (p=0.008)] and complexity of surgery [SCS (p<0.001)]. Age (p=0.002) and ASA (p=0.001) independently predicted mortality. LOS independently correlated with age (p=0.007), albumin (p=0.004), SCS (p=0.002), and stage (p=0.024). ASA (p<0.001) and SCS (p=0.003) both impacted ability to receive chemotherapy. Observed to expected (O/E) ratios for dependent outcome variables were similar for all 3 institutions.
CONCLUSIONS: We demonstrate the benefits of a national system for studying outcomes in gynecologic surgery using a risk-adjusted model. We specifically find that endogenous patient factors and complexity of surgery are primary drivers of morbidity in ovarian cancer surgery. These data can successfully be used to formulate expected, risk-adjusted rates of complications thus providing a meaningful mechanism to identify areas ripe for quality improvement.

Entities:  

Mesh:

Year:  2007        PMID: 17602726     DOI: 10.1016/j.ygyno.2007.05.032

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  42 in total

1.  Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

Authors:  Martina Aida Angeles; Federico Migliorelli; Mathilde Del; Carlos Martínez-Gómez; Manon Daix; Sarah Bétrian; Erwan Gabiache; Gisèle Balagué; Sophie Leclerc; Eliane Mery; Laurence Gladieff; Gwénaël Ferron; Alejandra Martinez
Journal:  Arch Gynecol Obstet       Date:  2021-01-03       Impact factor: 2.344

2.  Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer.

Authors:  Melissa M Thrall; Heidi J Gray; Rebecca Gaston Symons; Noel S Weiss; David R Flum; Barbara A Goff
Journal:  Gynecol Oncol       Date:  2011-09-26       Impact factor: 5.482

3.  Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

Authors:  Zhaomin Xu; Adan Z Becerra; Carla F Justiniano; Christopher T Aquina; Fergal J Fleming; Francis P Boscoe; Maria J Schymura; Abdulrahman K Sinno; Jessica Chaoul; Gary R Morrow; Lori Minasian; Sarah M Temkin
Journal:  J Surg Res       Date:  2019-09-24       Impact factor: 2.192

4.  Preoperative hypoalbuminemia is a risk factor for 30-day morbidity after gynecological malignancy surgery.

Authors:  Jin Kim; Seung-Hyuk Shim; In-Kyoung Oh; Sang-Hee Yoon; Sun-Joo Lee; Soo-Nyung Kim; Soon-Beom Kang
Journal:  Obstet Gynecol Sci       Date:  2015-09-22

5.  Changes in short-term health-related quality of life in women undergoing gynecologic oncologic laparotomy: an associated factor analysis.

Authors:  Lucas Minig; Jorge Iván Vélez; Edward L Trimble; Roberto Biffi; Angelo Maggioni; Diana D Jeffery
Journal:  Support Care Cancer       Date:  2012-08-29       Impact factor: 3.603

6.  Improving quality of care: development of a risk-adjusted perioperative morbidity model for vaginal hysterectomy.

Authors:  Christine A Heisler; Giovanni D Aletti; Amy L Weaver; L Joseph Melton; William A Cliby; John B Gebhart
Journal:  Am J Obstet Gynecol       Date:  2009-08-18       Impact factor: 8.661

7.  The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

Authors:  Gretchen Glaser; Michelle Torres; Bohyun Kim; Giovanni Aletti; Amy Weaver; Andrea Mariani; Lynn Hartmann; William Cliby
Journal:  Gynecol Oncol       Date:  2013-05-11       Impact factor: 5.482

8.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

9.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

10.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Svetlana Mironov; Revathy B Iyer; Qin Zhou; Alexia Iasonos; Harold Paul; Masayoshi Hosaka; Carol A Aghajanian; Mario M Leitao; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2014-07-11       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.